Peak neutralizing antibody–magnitude breadth curves.

<p>Average magnitude-breadth (MB) curves in the TZM-bl assay at peak immunogenicity (2 weeks post last vaccination) by treatment group. The area under the curve (AUC)-MB across all subjects in each group was calculated as the average of the log10 neutralizing antibody titers over the panel of 5 virus isolates (Tier 1: Clade B [MN.3, SF162], Clade C [MW965.26]; Tier 2: Clade C [Du151.2, TV1.21]). T1: MVA prime, sequential gp140 boost (M/M/P/P); T2 (MP/MP): concurrent MVA/gp140; T3 (D/D/M/M): DNA prime, sequential MVA boost; T4(D/D/MP/MP): DNA prime, concurrent MVA/gp140 boost) or placebo. Holm-Bonferroni adjusted p-values from unequal-variance t-tests were used for testing different mean AUC-MBs between vaccine arms accounting for the six pairs of vaccine arm comparisons.